281 related articles for article (PubMed ID: 2783611)
21. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
Aubin N; Barneoud P; Carter C; Caille D; Sontag N; Marc C; Lolivier J; Gardes A; Perron C; Le Kim A; Charieras T; Pandini M; Burnier P; Puech F; Jegham S; George P; Scatton B; Curet O
J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of types A and B monoamine oxidase by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Fuller RW; Hemrick-Luecke SK
J Pharmacol Exp Ther; 1985 Mar; 232(3):696-701. PubMed ID: 3871853
[TBL] [Abstract][Full Text] [Related]
23. Pharmacology of moclobemide.
Haefely W; Burkard WP; Cesura A; Colzi A; Kettler R; Lorez HP; Martin JR; Moreau JL; Richards JG; Schaffner R
Clin Neuropharmacol; 1993; 16 Suppl 2():S8-18. PubMed ID: 8313402
[TBL] [Abstract][Full Text] [Related]
24. [Comparison of the new MAO-A inhibitors moclobemide, brofaromine and toloxatone with tranylcypromine in an animal experiment: significance for clinical practice].
Da Prada M; Keller HH; Kettler R
Psychiatr Prax; 1989 Aug; 16 Suppl 1():18-24. PubMed ID: 2587673
[TBL] [Abstract][Full Text] [Related]
25. Neurochemical effects in vitro and in vivo of the antidepressant Ro 11-1163, a specific and short-acting MAO-A inhibitor.
Da Prada M; Kettler R; Keller HH; Haefely WE
Mod Probl Pharmacopsychiatry; 1983; 19():231-45. PubMed ID: 6865966
[No Abstract] [Full Text] [Related]
26. Synthesis, conformational analysis and antidepressant activity of moclobemide new analogues.
Ghanbarpour A; Hadizadeh F; Piri F; Rashidi-Ranjbar P
Pharm Acta Helv; 1997 Apr; 72(2):119-22. PubMed ID: 9112832
[TBL] [Abstract][Full Text] [Related]
27. Pre-clinical pharmacology of moclobemide. A review of published studies.
Burkard WP; Da Prada M; Keller HH; Kettler R; Haefely W
Br J Psychiatry Suppl; 1989 Oct; (6):84-8. PubMed ID: 2695131
[TBL] [Abstract][Full Text] [Related]
28. [3H]Ro 19-6327: a reversible ligand and affinity labelling probe for monoamine oxidase-B.
Cesura AM; Galva MD; Imhof R; Kyburz E; Picotti GB; Da Prada M
Eur J Pharmacol; 1989 Mar; 162(3):457-65. PubMed ID: 2744079
[TBL] [Abstract][Full Text] [Related]
29. Deamination of norepinephrine, dopamine, and serotonin by type A monoamine oxidase in discrete regions of the rat brain and inhibition by RS-8359.
Kumagae Y; Matsui Y; Iwata N
Jpn J Pharmacol; 1991 Jan; 55(1):121-8. PubMed ID: 1904113
[TBL] [Abstract][Full Text] [Related]
30. [Effect of benzamide derivatives on rat brain monoamine oxidase activity in vitro].
Gol'dina OA; Zagorevskiĭ VA; Lopatina KI; Sokolova TV; Gankina EM
Biull Eksp Biol Med; 1986 Aug; 102(8):170-2. PubMed ID: 3742029
[TBL] [Abstract][Full Text] [Related]
31. On the reversibility of reversible MAO inhibitors.
Waldmeier PC
Naunyn Schmiedebergs Arch Pharmacol; 1985 May; 329(3):305-10. PubMed ID: 4022138
[TBL] [Abstract][Full Text] [Related]
32. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers.
Illi A; Sundberg S; Ojala-Karlsson P; Scheinin M; Gordin A
Clin Pharmacol Ther; 1996 Apr; 59(4):450-7. PubMed ID: 8612391
[TBL] [Abstract][Full Text] [Related]
33. Design and early clinical evaluation of selective inhibitors of monoamine oxidase.
Palfreyman MG; McDonald IA; Bey P; Schechter PJ; Sjoerdsma A
Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(6):967-87. PubMed ID: 3266532
[TBL] [Abstract][Full Text] [Related]
34. Monoamine oxidase-inhibiting properties of SR 95191, a new pyridazine derivative, in the rat: evidence for selective and reversible inhibition of monoamine oxidase type A in vivo but not in vitro.
Kan JP; Steinberg R; Leclercq J; Worms P; Biziere K
J Neurochem; 1988 Apr; 50(4):1137-44. PubMed ID: 3346672
[TBL] [Abstract][Full Text] [Related]
35. E2011 a novel, selective and reversible inhibitor of monoamine oxidase type A.
Kagaya T; Kajiwara A; Nagato S; Akasaka K; Kubota A
J Pharmacol Exp Ther; 1996 Jul; 278(1):243-51. PubMed ID: 8764357
[TBL] [Abstract][Full Text] [Related]
36. Monoamine oxidase-A inhibitors and dopamine metabolism in rat caudatus: evidence that an increased cytosolic level of dopamine displaces reversible monoamine oxidase-A inhibitors in vivo.
Colzi A; D'Agostini F; Cesura AM; Borroni E; Da Prada M
J Pharmacol Exp Ther; 1993 Apr; 265(1):103-11. PubMed ID: 8473998
[TBL] [Abstract][Full Text] [Related]
37. Some basic aspects of reversible inhibitors of monoamine oxidase-A.
Da Prada M; Kettler R; Burkard WP; Lorez HP; Haefely W
Acta Psychiatr Scand Suppl; 1990; 360():7-12. PubMed ID: 2248079
[TBL] [Abstract][Full Text] [Related]
38. Moclobemide, an inhibitor of MAO-A, does not increase daytime plasma melatonin levels in normal humans.
Scheinin M; Koulu M; Vakkuri O; Vuorinen J; Zimmer RH
Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(1):73-82. PubMed ID: 2300680
[TBL] [Abstract][Full Text] [Related]
39. Relationship between tyramine potentiation and monoamine oxidase (MAO) inhibition: comparison between moclobemide and other MAO inhibitors.
Zimmer R
Acta Psychiatr Scand Suppl; 1990; 360():81-3. PubMed ID: 2248084
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors: moclobemide and selegiline.
Dingemanse J; Kneer J; Wallnöfer A; Kettler R; Zürcher G; Koulu M; Korn A
Clin Neuropharmacol; 1996 Oct; 19(5):399-414. PubMed ID: 8889283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
